Cardiology articles within Nature Reviews Clinical Oncology

Featured

• News & Views | 11 April 2023

  Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis

  Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective treatment strategies. Herein, we discuss a recent report of a series of patients who were managed using a novel approach that involved personalized abatacept dosing, ruxolitinib and close respiratory monitoring, which was associated with low mortality.

  • Douglas B. Johnson
  •  & Alexander M. Menzies

• In Brief | 20 December 2018

  Apixaban reduces risk of thromboembolism

  • Peter Sidaway

• Review Article | 24 November 2015

  Breast cancer therapy-associated cardiovascular disease

  Use of radiotherapy or chemotherapy generally increases the survival of women with breast cancer; however, the use of radiotherapy, chemotherapy agents, such as the anthracycline doxorubicin, or anti-HER2 agents, such as trastuzumab, confer an increased risk of adverse cardiovascular events in these patients. In this Review, the authors describe the incidence and management of treatment-induced cardiac disease in women with breast cancer, and highlight strategies that might be used to minimize this risk.

  • Timothy M. Zagar
  • , Daniela M. Cardinale
  •  & Lawrence B. Marks